Prevention of graft vessel disease by combined FTY720/cyclosporine a treatment in a rat carotid artery transplantation model

Transplantation

Volumn 69, Issue 12, 2000, Pages 2525-2530

  Nikolova, Zariana ^a   Hof, Akiko ^a   Rudin, Markus ^a   Baumlin, Yves ^a   Kraus, Gerolf ^a   Hof, Robert P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FINGOLIMOD;

ANIMAL EXPERIMENT; ARTERY TRANSPLANTATION; ARTICLE; CAROTID ARTERY; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; GRAFT REJECTION; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

EID: 0034720758     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006270-00010     Document Type: Article

References (25)

1. Häyry P, Mennander A, Yilmaz S, et al. Towards understanding the pathophysiolbgy of chronic rejection. Clin Invest 1992; 70: 780.
2. Adams DH, Tilney NL, Collins Jr JJ, Karnovsky MJ. Experimental Graft Arteriosclerosis. I. The Lewis-to-F344 allograft model. Transplantation 1992; 53: 1115.
3. Häyry P, Alatalo S, Myllärniemi M, Räisänen-Sokolowski A, Lemström K. Cellular and molecular biology of chronic rejection. Transplant Proc 1995; 27: 71.
4. Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg 1988; 7: 82.
5. Geerling RA, De Bruin RWF, Scheringa M, et al. Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat. Transplantation 1994; 58: 1258.
6. Isik FF, McDonald TO, Ferguson M, Yamanaka E, Gordon D. Transplant arteriosclerosis in a rat aortic model. Am J Pathol 1992; 141: 1139.
7. Wehr S, Rudin M, Joergensen J, Hof A, Hof RP. Allo-and autotransplantation of carotid artery - a new model of chronic graft vessel disease. Transplantation 1997; 64: 20.
8. Hancock WW, Shi C, Picard MH, Bianchi C, Russell ME. Lewto-F344 carotid artery allografts: analysis of a rat model of posttransplant vascular injury involving cell-mediated and humoral responses. Transplantation 1995; 60: 1565.
9. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037.
10. Chiba K, Yanagawa Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Transplant Proc 1999; 31: 1230.
11. Troncoso P, Stepkowski SM, Wang, M-E, et al. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. Transplantation 1999; 67: 145.
12. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effects in combination with cyclosporine in rats. Transplant Proc 1996; 28: 1056.
13. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493.
14. Hoshino Y, Suzuki C, Ohtsuki M, Masubuchi Y, Amano Y, Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 1996; 28: 1060.
15. Kawaguchi T, Hoshino Y, Rahman F, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplant Proc 1996; 28: 1062.
16. Cook NS, Zerwes H-G, Pally C, Rudin M, Hof RP. Spirapril and Cilazapril inhibit neointimal lesion development but cause no detectable inhibition of lumen narrowing after carotid artery balloon catheter injury in the rat. Blood Press 1993; 2: 322.
17. Cook, NS, Zerwes H-G, Pally C, Rudin M, Hof RP. Decreased lumen size after balloon injury despite inhibition of neointimal thickening and antivasospastic treatment. Cardiovasc Res 1994; 28: 215.
18. Little DM, Stoltenberg RL, Hullett DA, Sollinger HW. Effect of Neoral or Cyclosporine on the development of chronic rejection in an aortic allograft rat model. Transplant Proc 1996; 28: 880.
19. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest 1986; 55: 455.
20. Ferns G, Reidy M, Ross R. Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol 1990; 137: 403.
21. Bossaller C, Forstermann U, Hertel R, Olbricht C, Reschke V, Fleck E. Ciclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165.
22. Suzuki T, Shimamura T, Jin, MB, et al. Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. Transplant Proc 1999; 31: 1208.
23. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200.
24. Wang M-E, Tejpal N, Qu X, et al. Immunosuppressive effects of FTY720 alone or in combination with Cyclosporine and/or Sirolimus. Transplantation 1998; 65: 899.
25. Stepkowski SM, Wang M-E, Qu X, et al. Synergistic interaction of FTY720 with Cyclosporine or Sirolimus to prolong heart allograft survival. Transplant Proc 1998; 30: 2214.